Sustained TTR Inhibition in ATTR Amyloidosis for Over Two Years with a Single Injection, Demonstrating Safety
Background and Challenges
ATTR amyloidosis is a disease in which the transthyretin (TTR) protein abnormally accumulates in tissues, causing damage to multiple organs. Existing therapies require periodic administration and carry a risk of adverse effects, substantially reducing patients' quality of life.
Innovative Research Approach and Findings
The research team evaluated a novel RNA interference agent, ART001, administered as a single dose to ten patients across a dose range of 0.05 mg/kg to 1 mg/kg. In the six participants receiving 0.7 mg/kg or 1 mg/kg, mean TTR protein reductions of 84% and 92%, respectively, were observed at week 72, and this effect persisted for at least 72 weeks post‑dose. Notably, no infusion‑related reactions (IRRs) or serious adverse events (SAEs) or serious adverse reactions (SARs) were reported.
Future Implications and Outlook
These results demonstrate the feasibility of achieving long‑term TTR suppression with a single injection, potentially transforming the therapeutic paradigm for ATTR amyloidosis. If large‑scale clinical trials and extended safety evaluations confirm these findings, patients could be liberated from complex dosing schedules, leading to substantial improvements in quality of life.
BACKGROUND: ATTR amyloidosis is a disease caused by abnormal deposition of TTR (transthyretin) protein in tissues. ART001 is an METHODS: In an investigator-initiated trial (IIT) of ART001 for 10 ATTR Amyloidosis patients, each patient was given one dose of ART001 which ranged from 0.05 mg/kg to 1.0 mg/kg. The aim was to evaluate ART001's safety, side effects, PK, PD, and efficacy based on circulating TTR protein levels. RESULTS: At 0.7 mg/kg in 3 subjects and 1 mg/kg in 3 subjects, TTR protein reductions averaged 84 and 92% at 72 weeks. No infusion-related reactions (IRRs), serious adverse events (SAEs) or serious adverse reactions (SARs) were observed. CONCLUSION: A single injection of ART001 achieved > 80% TTR knock-down at doses > 0.5 mg/kg and lasted for at least 72 weeks without IRRs, SARs or SAEs. ART001 has the potential to be a safe, effective and permanent therapeutic option for ATTR Amyloidosis patients. (Funded by Accuredit Therapeutics). CLINICAL TRIAL REGISTRATION: Trial registration: ChiCTR, ChiCTR2400081216. Registered 26
Patients with ATTR amyloidosis currently endure continuous medication regimens and the associated risk of adverse effects. If disease progression can be halted for years with a single injection, the therapeutic burden would be markedly reduced, making daily life considerably more comfortable.